Cadila Healthcare’s US subsidiary has received approval for anti-obsessional drug, from the US health regulator.

In a filing the company stated that, Zydus Pharmaceuticalst (USA) Inc, a wholly owned subsidiary of Cadila Healthcare, has received final approval to market Clomipramine Hydrochloride capsules USP, from the US Food and Drug Administration.

The approved product will be used to treat obsessive compulsive disorder which is characterized by uncontrollable, re-occurring thoughts (obsessions) and behaviours (compulsions) and these capsules will be available in strengths of 25 mg, 50 mg and 75 mg.

Read EquityPandit’s Technical Analysis of Nifty Pharma Outlook for the Week